32760206 2020. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
32767348 2020. Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management?
33182059 2020. Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.
33254564 2020. Role of inositol to improve surfactant functions and reduce IL-6 levels: A potential adjuvant strategy for SARS-CoV-2 pneumonia?
33292350 2020. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
C7303599 2020. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.
33066442 2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.
33063409 2020. Treatment of Stage 3 COVID-19 With Transcutaneous Auricular Vagus Nerve Stimulation Drastically Reduces Interleukin-6 Blood Levels: A Report on Two Cases.
33146673 2020. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.
33204749 2020. Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy.
33214204 2020. Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia.
33262810 2021. Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).
| 33270024 2020. Therapeutic targeting of interleukin-6 for the treatment of COVID-19.
|
C7320867 2020. Rethinking interleukin-6 blockade for treatment of COVID-19.
| 32920514 2020. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
|
32955921 2020. Is Interleukin 6 the Right Target in COVID-19 Severe Pneumonia?
